Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (457)	12/23/2003 11:04:29 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

LJPC Is up only 9.27% today, but it is now breaking out of the downtrend which started from the Sep.17-Sep.24 double top at the 5.21 level.<g> Last week it announced that it had submitted an NDA for Riquent,which is its drug candidate for the treatment of lupus patients at risk of renal disease. biz.yahoo.com The results from the PIII showed that Riquent was well tolerated. However, an initial assessment of the data indicated that treatment with Riquent did not increase length of time to renal flare, the primary endpoint, in a statistically significant manner.There were 298 patients in the intent-to-treat population, 145 on Riquent and 153 on placebo. The stock is trading at 3.77 on a volume of more than 925K and over its Dec.16 H of 3.53 and Nov.3 H of 3.54 <g> siliconinvestor.com Bernard